Heterogeneous response to target therapy in metastatic papillary renal cell carcinoma evaluated by morphologic and metabolic multimodality imaging: A case report

RATIONALE: Papillary renal cell carcinoma (PRCC) accounts for about 15% to 20% of renal cell carcinoma and is histologically distinguished in type I and type II. The last one is associated with poorer prognosis. Treatment options for PRCC patients are surgery, immunotherapy, revolutionized by Nivolu...

Descripción completa

Detalles Bibliográficos
Autores principales: Naglieri, Emanuele, Niccoli Asabella, Artor, Nappi, Anna Giulia, Carella, Claudia, Ferrari, Cristina, Rubini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
6800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922556/
https://www.ncbi.nlm.nih.gov/pubmed/31852068
http://dx.doi.org/10.1097/MD.0000000000018093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922556/
https://www.ncbi.nlm.nih.gov/pubmed/31852068
http://dx.doi.org/10.1097/MD.0000000000018093

Ejemplares similares